Академический Документы
Профессиональный Документы
Культура Документы
“Growth means change and change involves risk, stepping from known to unknown”
-Anonymous.
NCE’s. 6 NCE’s from own R&D and In May 2009, Ranbaxy made an
2 in alliance with GlaxoSmithKline. alliance with Daiichi Sankyo, a
Ranbaxy is not only involved in Japanese pharma company. Daiichi
developing novel delivery systems Sankyo took 63.9% of Ranbaxy’s
but is also working in collaboration share and with this mutually hybrid
to develop of new drug model Ranbaxy’s risk was reduced
(Ranbaxy,2009). and its opportunities as an
originator companies increased.
On the other hand Biocon has
While Biocon has sold its enzymes
established Syngene to carry out
development business to
customized research and Clingene
Novozymes to focus on biotech and
carries out clinical research and
Pharmaceutical products and has
development and is working as a
emerged as a Biopharmaceutical
self sufficient organization
company with a promising pipeline
(Biocon,2008).
(Ranbaxy,2009).
Ranbaxy followed a diversification
By alliance with Ranbaxy, Daiichi
business model. This model
Sankyo gained access to India
involves marketing of large number
market and it entered into generic
of drugs in small market although
market. Sankyo got advantage of
sales were not equivalent to
marketing their products in
blockbuster drug. But developing
Ranbaxy’s areas and got access to
blockbuster drug is very costly and
low cost facilities of Ranbaxy,
by this model company generated
where Ranbaxy got access to
substantial amount of funds
Japanese market, R&D and
(Pharmaceutical and drug
infrastructure of Daiichi and above
manufacturers, 2009).
all Ranbaxy got rid of its debt
Biocon is following an intermediate (Ranbaxy,2009).
business model of blockbuster and
• Future Trends
diversification as they have
blockbuster drug in their pipeline
– Use of novel technologies in
which can generate huge sales for
the drug discovery and high
small number of drugs and to
use of in vitro and animal
generate funds they are marketing
data to predict the
drugs in small markets which has
pharmacological action of the
high treatment cost. Their business
drug thereby limiting the
model also involves horizontal
failure rates.
integration that means acquisition
– Use of genomic and
of extra business activity at the
nanotechnology knowledge
same level( Nabin,2009).
to develop drugs with wider
50904989 Bio-business essay